• Home
  • Investor Education
    • Essential Tips for Stock Investors
    • Using Passive Investing to Beat the Market
    • Recommended Investment Books
    • Key Things to note in Rights Issues
    • Understanding Reverse Takeovers
    • Stock Split vs Bonus Issue
  • Latest Recommendations
    • Abric Berhad
    • Kejuruteraan Samudra Timur
    • Chuan Hup Holdings
    • Falcon Energy Group
    • Memstar Technology
    • Pacific Century Regional Developments
    • Singapore Healthcare Stocks
    • Macquarie Int Infrastructure Fund
    • IPC Corporation
    • Tiger Airways
    • TSH Corporation
    • Bukit Sembawang Estates
    • HG Metal Manufacturing
    • OKP Holdings
    • Global Investments Ltd
    • Baker Technology Ltd
    • Yongnam Holdings
    • Hupsteel
    • TIH
    • Sysma Holdings
    • Sembcorp Industries
Stock Investment Research with an Asian focus

Pacific Century Regional Developments Ltd (PCRD)- Update

5/5/2015

 
Key developments since our first report:

  1. Two weeks after our report published on 16 April 2015, Business Times ran a similar article on 30 April 2015 highlighting the potential delisting of PCRD as well as a possible restructuring of the group:http://business.asiaone.com/news/pacific-century-headed-delisting (note: link is to the said article reproduced on asiaone.com as Business Times operates a paid platform that might not be available to all readers)
  2. In the same two-week period, PCRD's share price has advanced more than 28% to close at $0.445 on 30 April 2015. It has since cooled slightly to $0.435 as at 4 May 2015. 
  3. On 2 May 2015, PCRD released an announcement clarifying that "it is not aware of, and has not received, any proposal in relation to privatisation of the Company. In addition, the Company is not aware of any restructuring plan involving the Company and its subsidiaries."
  4. PCRD has successfully obtained a fresh mandate for share repurchases up to 10% of its shares and gone on to record its first purchase on 29 April 2015 at $0.405 per share, a sharply higher price than its previous purchase at $0.365 per share a week before.   

Our Views

We do not see the company's response as anything more than routine and it does not in our opinion reduce the likelihood of a privatisation happening in the future. It merely confirms that an offer or restructuring proposal has not been tabled or discussed officially as at the announcement date. 

Under the current regulatory regime, there are a few ways that PCRD's privatisation could take place: through a general offer, a scheme of arrangement, a voluntary delisting or a forced delisting by SGX due to low free float (<10%) coupled with an exit offer. Based on current circumstances, we see the last two as the most likely options. Both would require a reasonable exit offer to be tabled and the appointment of an independent financial adviser ("IFA") to opine on the fairness of the offer as stipulated in the SGX listing rules. We note that IFAs tend to benchmark fair value of a company's shares to the market prices of its underlying assets where such values are available as in the case of PCRD. As such, we do not expect any exit offer, if it materialises, to deviate greatly from the fair value computed using this methodology in order to obtain a positive recommendation from the IFA. 

Recommendations

We continue to believe that PCRD is undervalued although we note that the valuation gap between the current market price of $0.435 and the implied fair value of $0.542 which we previously computed has closed significantly to 19.7% (vs 36.4%). Downside risks though, should be limited as the Company has reconvened its share repurchases at a sharply higher price of $0.405 per share lending further support to the share price.  
    Like our Facebook page for the latest updates:
    Follow @StockResearchA
    RSS Feed Widget

    Author

    StockResearchAsia Team

    Archives

    June 2020
    November 2019
    July 2019
    June 2019
    March 2019
    January 2019
    September 2018
    June 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    September 2017
    July 2017
    June 2017
    February 2017
    September 2016
    May 2016
    March 2016
    January 2016
    December 2015
    November 2015
    September 2015
    August 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015

    Categories

    All
    Abric Berhad
    Asia Enterprises Holding Ltd
    Bukit Sembawang Estates Ltd
    Bursa
    Ch Offshore Ltd
    Chuan Hup Holdings Ltd
    Corporate Action
    E2-Capital Holdings Ltd
    Falcon Energy Group Ltd
    Finbar Group Limited
    Healthcare Sector
    Health Management International Ltd
    HG Metal Manufacturing Ltd
    Hkt
    Hupsteel Ltd
    Ipc Corporation Ltd
    Ipos
    Irving Kahn
    Jaya Holdings Ltd
    Kejuruteraan Samudra Timur Berhad
    Keppel Corporation
    Macquarie International Infrastructure Fund
    Memstar Technology Ltd
    OKP Holdings Ltd
    Pacific Century Regional Developments Ltd
    Pccw Ltd
    Pci Ltd
    Pcpd Ltd
    Privatisation
    Raffles Medical Group Ltd
    Rtos
    Scomi Energy Berhad
    Sembcorp Industries
    Sembcorp Marine
    Sgx
    Singapore Airlines Ltd
    Singapore O&G Ltd
    Special Situations
    Sysma Holdings
    Takeover Offer
    Talkmed Group Ltd
    Tiger Airways Holdings Ltd
    TIH Ltd
    Tsh Corporation Ltd
    Value Investor
    Year End Review
    Yongnam Holdings Ltd

    RSS Feed

IMPORTANT NOTICE
We put money where our mouth is. As such, we do take positions in the securities mentioned on this website or any securities related thereto and may from time to time add or dispose of or may be materially interested in any such securities. The research materials provided on this site is for information only. Investors should seek the assistance of a qualified and licensed financial advisor in making their investment decisions. The research reports/notes are compiled based on information, which we believe to be reliable. Any opinions expressed reflect our judgment at as at the date of the reports or notes and are subject to change without notice. It does not have regards to the specific investment objectives, financial situation and the particular needs of any specific person who may receive or access this research material. Our recommendations are not to be construed as an offer, or solicitation of an offer to sell or buy securities referred herein. The use of this material does not absolve you of your responsibility for your own investment decisions. We accept no liability for any direct or indirect loss arising from the use of this research material. This research material may not be reproduced, distributed or published for any purpose by anyone without our specific prior consent.